AN
ANPCF.US ANGLE plc
- Market cap
- USD 11.1M
- P/E
- -
- P/B
- 2.03x
- ROE
- -271.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is ANPCF.US undervalued?
Graham numberThe Graham number of ANGLE plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ANGLE plc fundamental analysis
No fundamental analysis for ANGLE plc yet.
ANGLE plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ANGLE plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and …
Full company profileANGLE plc financial statements
ANGLE plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 498K | 628K | 678K | - | 762K | 1.01M | 1.04M | 2.19M | 2.86M | 1.35M |
| Gross Profit | 375K | 459K | 523K | - | 597K | 711K | 613K | 1.53M | 1.78M | 832K |
| Operating Income | -7.44M | -8.93M | -10.9M | - | -13.7M | -17.2M | -24.2M | -20.5M | -15.5M | -15.4M |
| EBITDA | -6.92M | -8.14M | -9.83M | - | -12.2M | -15.7M | -21.2M | -19.0M | -13.0M | -13.5M |
| Net Income | -6.57M | -7.56M | -8.94M | - | -11.6M | -15.0M | -21.7M | -20.1M | -14.2M | -19.5M |
| EPS | -0.09 | -0.08 | -0.07 | - | -0.07 | -0.07 | -0.09 | -0.08 | -0.04 | -0.02 |
| Balance Sheet | ||||||||||
| Total Assets | 10.9M | 18.3M | 23.0M | - | 39.0M | 47.3M | 49.9M | 31.2M | 25.5M | 12.6M |
| Total Liabilities | 2.11M | 2.40M | 3.68M | - | 4.71M | 6.99M | 9.81M | 8.24M | 7.02M | 5.39M |
| Shareholders' Equity | 8.81M | 15.9M | 19.3M | - | 34.3M | 40.3M | 40.1M | 22.9M | 18.4M | 7.20M |
| Cash & Short-term Investments | 5.54M | 7.65M | 11.0M | - | 28.6M | 31.8M | 31.9M | 16.2M | 10.4M | 7.35M |
| Total Debt | - | - | - | - | 1.36M | 2.34M | 5.00M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -7.38M | -6.81M | -7.31M | -12.5M | -7.85M | -14.0M | -16.1M | -14.5M | -13.4M | -9.26M |
| Capital Expenditure | 444K | 1.86M | 1.35M | 794K | 506K | 1.79M | 1.89M | 660K | 444K | 249K |
| Free Cash Flow | -7.83M | -8.67M | -8.67M | - | -8.35M | -15.8M | -17.9M | -15.1M | -13.9M | -9.51M |
| Ratios | ||||||||||
| ROE | -74.6% | -47.6% | -46.2% | - | -33.8% | -37.2% | -54.1% | -87.8% | -77.1% | -271.1% |
| ROA | -60.1% | -41.3% | -38.8% | - | -29.7% | -31.7% | -43.5% | -64.6% | -55.9% | -155.0% |
| Net Profit Margin | -1,318.7% | -1,203.2% | -1,318.9% | - | -1,523.1% | -1,481.9% | -2,083.2% | -921.0% | -497.0% | -1,444.0% |
| Debt to Equity | - | - | - | - | 0.04x | 0.06x | 0.12x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ANGLE plc dividends
ANGLE plc has not paid dividends in the last 10 fiscal years.
Who owns ANGLE plc
- Insiders 4.70%
- Institutions 33.30%
- Public & others 62.01%
- Shares outstanding 1.14B
- Free float 492M
ANGLE plc company profile
- Company name
- ANGLE plc
- Ticker
- ANPCF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 114
- Fiscal year end
- December
- Address
- Surrey Research Park, Guildford, United Kingdom, GU2 7AF
- Phone
- 44 14 8334 3434
- Website
- cellbxhealth.com
About ANGLE plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
ANGLE plc management
6- Ms. Sinéad Eithne ArmstrongFinance Director
- Dr. Lavanya SivapalanChief Scientific Officer
- Ms. Michelle MunsonChief of Staff
- Dr. Lauren Arthy-MilesESG Lead
- Dr. Cristina CiccioliHead of Assay Development
- Christina DorrisChief Commercial Officer